Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tianxiao, Luo, Songyuan, Libby, Peter, Shi, Guo-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255230/
https://www.ncbi.nlm.nih.gov/pubmed/32470470
http://dx.doi.org/10.1016/j.pharmthera.2020.107587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255230/
https://www.ncbi.nlm.nih.gov/pubmed/32470470
http://dx.doi.org/10.1016/j.pharmthera.2020.107587

Ejemplares similares